PMID- 36730521 OWN - NLM STAT- MEDLINE DCOM- 20230206 LR - 20230206 IS - 1365-2230 (Electronic) IS - 0307-6938 (Linking) VI - 48 IP - 2 DP - 2023 Feb 2 TI - Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. PG - 80-88 LID - 10.1093/ced/llac040 [doi] AB - BACKGROUND: Molecular skin profiling techniques, typically performed on skin samples taken by punch biopsy, have enhanced the understanding of the pathophysiology of atopic dermatitis (AD), thereby enabling the development of novel targeted therapeutics. However, punch biopsies are not always feasible or desirable, and novel minimally invasive methods such as skin tape stripping have been developed. AIM: To develop, optimize and validate a novel tape stripping method guided by noninvasive in vivo skin imaging to sample atopic skin in children. METHODS: Skin tape stripping-based procedures were compared and optimized using data from 30 healthy controls (HCs: 5 adults, 25 children) and 39 atopic children. Evaluations were guided by high-resolution photography, reflectance confocal microscopy, optical coherence tomography and transepidermal water loss measurements. We assessed and compared adverse events (AEs), the time needed to perform the sampling and the cDNA levels obtained from the tapes. RESULTS: Tape stripping methods based on previously described protocols resulted in erosions in all participants and required a median time of 65 min to perform (range 60-70 min), but provided good cDNA yield. Shorter durations appeared less invasive but provided lower cDNA yield. The final optimized tape stripping protocol, using 11 tapes of 22 mm in diameter, each applied twice for 5 s with 90 degrees rotation, did not produce significant AEs, was completed within a median time of 7 min (range 5-15 min) and provided good cDNA yield both in HCs and atopic children. CONCLUSION: Our minimally invasive method is safe and reliable, and provides reproducible acquisition of cDNA in atopic children. In addition, it enables rapid sample collection, a crucial factor in clinical practice. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of British Association of Dermatologists. FAU - Yelamos, O AU - Yelamos O AUID- ORCID: 0000-0002-8058-3095 AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. AD - Department of Dermatology, Hospital de la Santa Creu i Sant Pau, IIB SANT PAU, Universitat Autonoma de Barcelona, Barcelona, Spain. FAU - Andersen, D AU - Andersen D AD - Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. FAU - Pont, M AU - Pont M AD - Almirall R&D, Barcelona, Spain. FAU - Iglesias, P AU - Iglesias P AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. FAU - Potrony, M AU - Potrony M AUID- ORCID: 0000-0003-2766-0765 AD - Biochemistry and Molecular Genetics Department, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain. FAU - Dominguez, M AU - Dominguez M AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. FAU - Herrero, A AU - Herrero A AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. FAU - Alejo, B AU - Alejo B AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. FAU - Mateu, J AU - Mateu J AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. FAU - Ropke, M AU - Ropke M AD - LeoPharma A/S, Ballerup, Denmark. FAU - Danneskiold-Samsoe, N B AU - Danneskiold-Samsoe NB AD - Department of Biology, University of Copenhagen, Copenhagen, Denmark. FAU - Malvehy, J AU - Malvehy J AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain. FAU - Guy, R H AU - Guy RH AD - Department of Life Sciences, University of Bath, Bath, Somerset, UK. FAU - Brix, S AU - Brix S AD - Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark. FAU - Puig, S AU - Puig S AUID- ORCID: 0000-0003-1337-9745 AD - Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain. AD - Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain. LA - eng GR - Almirall S. A./ GR - Leo Pharma A/S/ PT - Journal Article PL - England TA - Clin Exp Dermatol JT - Clinical and experimental dermatology JID - 7606847 RN - 0 (DNA, Complementary) SB - IM MH - Adult MH - Humans MH - Child MH - *Dermatitis, Atopic/pathology MH - DNA, Complementary MH - Skin/pathology MH - Biopsy/methods MH - Specimen Handling/methods MH - Epidermis/pathology COIS- Conflict of interest OY has received consultancy honoraria from Almirall, Leo Pharma and Isispharma and speakers' honoraria from Isispharma, Pierre Fabre, Leo Pharma, BMS and MSD. MP and MR are employees from Almirall and Leo Pharma, respectively. SP has received consultancy honoraria from Almirall, Leo Pharma, Pfizer, Novartis, Sanofi, BMS, ISDIN, La Roche Posay, Regeneron, Sun Pharma, Roche and speakers' honoraria from Almirall, Leo Pharma, Pfizer, BMS, ISDIN, La Roche Posay, Regeneron, Sanofi, Sun Pharma, Roche. JM has received consultancy honoraria from Almirall, AMGEN, Canfield, Leo Pharma, BMS, ISDIN, Sun Pharma, Roche and speakers' honoraria from Almirall, BMS, ISDIN, Novartis, Sun Pharma, Roche, Pierre Fabre. MPy has received advisory honoraria from ISDIN. RHG has, in the past, acted as a paid consultant to Almirall and Leo Pharma and has received a research grant from Leo Pharma. The other authors declare that they have no conflict of interest. EDAT- 2023/02/03 06:00 MHDA- 2023/02/07 06:00 CRDT- 2023/02/02 14:14 PHST- 2022/03/25 00:00 [received] PHST- 2022/09/17 00:00 [revised] PHST- 2022/11/03 00:00 [accepted] PHST- 2023/02/02 14:14 [entrez] PHST- 2023/02/03 06:00 [pubmed] PHST- 2023/02/07 06:00 [medline] AID - 6815665 [pii] AID - 10.1093/ced/llac040 [doi] PST - ppublish SO - Clin Exp Dermatol. 2023 Feb 2;48(2):80-88. doi: 10.1093/ced/llac040.